A strategy to kill solid tumors in a tissue-agnostic manner
Atengen is developing drugs that target a novel receptor found in the blood vessels of most solid tumors. We are developing a new generation of therapeutics designed to kill tumors by killing tumor blood vessels.
Our target is highly specific; it is only found in tumor blood vessels.
At the same time, our target is very broad; it is present in the tumor blood vessels of most solid tumors.
Kills Tumor Blood Vessels
Our approach disrupts new tumor blood vessel growth that is mediated by multiple different angiogenic factors and results in the death of existing tumor blood vessels.
Suppress and Kill Solid Tumors
Our approach both suppresses tumor growth and kills existing tumors.
Less Susceptible to Mutagenesis
Since we are not targeting cancer cells, our approach is less susceptible to mutagenesis.